SCHEMBL3491807

SCHEMBL3491807

O=C(O)c1cc2c(=O)[nH]c(CC3=CCCC3)nc2s1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.56
BRD4 O60885 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
KMT2A Q03164 3/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 2/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 2/20 0.35
TMIGD3 P0DMS9 1/20 0.34
PARP1 P09874 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
POLB P06746 1/20 0.34
L3MBTL1 Q9Y468 3/20 0.33
MAPT P10636 2/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494101 0.97 PDE5A (0.55) PDE5ABRD4SMN1; SMN2KMT2ARAB9A
SCHEMBL4510358 0.85 PDE5A (0.44) PDE5ASMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL21153553 0.82 PDE5A (0.37) PDE5ABRD4SMN1; SMN2KMT2ARAB9A
SCHEMBL38093 0.79 PDE5A (0.55) PDE5ASMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3491566 0.79 ALDH1A1 (0.53) SMN1; SMN2KMT2ARAB9AMEN1NPC1
SCHEMBL3494163 0.77 PDE5A (0.79) PDE5ABRD4SMN1; SMN2KMT2ARAB9A
SCHEMBL3491341 0.76 ALDH1A1 (0.52) BRD4SMN1; SMN2KMT2ARAB9AMEN1
SCHEMBL13620444 0.75 PDE5A (0.54) PDE5AKMT2ARAB9AMEN1NPC1
SCHEMBL16175565 0.75 ALDH1A1 (0.42) BRD4SMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL3492972 0.74 PDE5A (0.67) PDE5ABRD4SMN1; SMN2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870656-B2 Methods for treatment of heart failure CARDURION PHARMACEUTICALS, LLC (US) 2020-12-22 US disclosed
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE CARDURION PHARMACEUTICALS LLC (US) 2019-07-11 US disclosed
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD PDE5A 14/4885BRD4 1812/4885SMN1; SMN2 3450/4885
US-10870656-B2 Methods for treatment of heart failure TNNT2, TNNI3, TNNC1 PDE5A 251/4885BRD4 2159/4885SMN1; SMN2 1014/4885
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 PDE5A 25/4885BRD4 2005/4885SMN1; SMN2 2219/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 PDE5A 25/4885BRD4 2005/4885SMN1; SMN2 2219/4885
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE TNNT2, TNNI3, TNNC1 PDE5A 251/4885BRD4 2159/4885SMN1; SMN2 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.